MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-06-30, ITOS has $623,083K in assets. $129,282K in debts. $207,820K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
752.76%
Cash Ratio
295.73%
Debt to Asset Ratio
20.75%
Assets Breakdown
    • Short-term investments (amortize...
    • Cash and cash equivalents
    • Long-term investments (amortized...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Unrecognized tax benefits
    • Others

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Balance Sheets
2025-06-30
Property and equipment, net
5,175
Short-term investments (amortized cost of 307,394)
307,610
Prepaid expenses and other current assets
11,015
Refundable income taxes
1,793
Grants receivable
475
Cash and cash equivalents
207,820
Research and development tax credits receivable
280
Total current assets
528,993
Restricted cash
319
Other assets
898
Right of use assets
5,129
Long-term investments (amortized cost of 74,475)
74,614
Research and development tax credits receivable, net of current portion
7,955
Total assets
623,083
Other accrued expenses
796
Lease liabilities
1,516
Accrued personnel expenses
23,774
Deferred income
1,477
Accounts payable
6,249
Accrued clinical trial costs
36,462
Total current liabilities
70,274
Unrecognized tax benefits
48,790
Lease liabilities, net of current portion
3,612
Grants repayable, net of current portion
6,606
Total liabilities
129,282
Accumulated deficit
-123,123
Common stock, 0.001 par value 150,000,000 shares authorized at march 31, 2025 and december 31, 2024 38,271,682 and 36,598,043 shares issued and outstanding, respectively
44
Additional paid-in capital
633,070
Accumulated other comprehensive loss
-16,190
Total stockholders equity
493,801
Total liabilities and stockholders equity
623,083
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Research and developmenttax credits...$280K Cash and cashequivalents$207,820K Grants receivable$475K Refundable income taxes$1,793K Prepaid expenses andother current assets$11,015K Short-term investments(amortized cost of 307,394)$307,610K Research and developmenttax credits...$7,955K Long-term investments(amortized cost of 74,475)$74,614K Right of use assets$5,129K Other assets$898K Restricted cash$319K Total current assets$528,993K Property and equipment,net$5,175K Total assets$623,083K Total liabilities andstockholders equity$623,083K Total stockholdersequity$493,801K Total liabilities$129,282K Accumulated othercomprehensive loss-$16,190K Accumulated deficit-$123,123K Additional paid-in capital$633,070K Grants repayable, netof current portion$6,606K Lease liabilities,net of current...$3,612K Unrecognized tax benefits$48,790K Total currentliabilities$70,274K Common stock, 0.001 parvalue 150,000,000...$44K Accrued clinical trialcosts$36,462K Accounts payable$6,249K Deferred income$1,477K Accrued personnelexpenses$23,774K Lease liabilities$1,516K Other accruedexpenses$796K

iTeos Therapeutics, Inc. (ITOS)

iTeos Therapeutics, Inc. (ITOS)